May 31, 2019
May 31, 2019
It’s Hepatitis Awareness Month!
Congratulations to Prof. Antonio Bertoletti, Scientific Founder of Lion TCR Pte Ltd in receiving the recognition as TOP 0.1% WORLD EXPERT in the area of HEPATITIS B over the past 10 years (by Expertscape).
Prof. Bertoletti is also a Professor at Duke-NUS and Agency for Science and Technology (A*STAR). At Lion TCR, our mission is to develop TCR T cell therapy against virus-infected cancer and viral infections. We Hunt Viruses!
Lion TCR Announces Data Presentation for its lead T-cell product, LioCyx-M at EASL Digital Liver Cancer Summit 2021
HSA approval for Phase 1 IND clinical trial for Lion TCR’s lead product LioCyx-M to characterize changes in liver cancer tumor microenvironment
Lion TCR presents two abstracts of Phase 1 clinical trial data for lead product LioCyx-M at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Companion diagnostic assay for personalised immunotherapy for HBV-related liver cancer featured in A*STAR GIS website
Singapore’s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
Scientific Founder, Prof. Antonio Bertoletti and Scientific Consultant, Dr Anthony Tanoto Tan of Lion TCR were awarded the SingHealth Duke-NUS Research Award 1st Prize 2018
US FDA grants Lion TCR two orphan drug designations of T cell therapy against Hepatocellular Carcinoma
New publication – Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient